Ten of 12 ginseng supplements evaluated met CL standards for quality, label claims, disintegration and lack of contaminants and adulterants, online testing company announces Aug. 28. MotherNature.com's Korean ginseng had high levels of the pesticides hexachlorobenzene, quintozene, lindane, while Royal King's Chinese ginseng contained less than 10% of the claimed amount of ginsenosides, CL reports. Nature's Way herbal single Korean ginseng and Vitamin World's Chinese red ginseng were among the products that contained the proper amount of ginsenosides and that did not exceed acceptable levels of contaminants. CL last tested ginseng supplements in July 2000; the firm's findings of pesticide contamination in eight of 22 brands tested were featured on ABC News' 20/20 (1"The Tan Sheet" July 17, 2000, p. 15)...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
